Literature DB >> 8429341

Potential gallium-68 tracers for imaging the heart with PET: evaluation of four gallium complexes with functionalized tripodal tris(salicylaldimine) ligands.

M A Green1, C J Mathias, W L Neumann, P E Fanwick, M Janik, E A Deutsch.   

Abstract

Gallium-67 and 68Ga complexes have been synthesized with tripodal hexadentate salicylaldimine ligands derived from 1,1,1-tris(salicylaldiminomethyl)ethane, sal3tame. The four ligands evaluated contained alkoxy substituents (n-BuO-, iso-BuO-, sec-BuO-, and n-PrO-) on the terminal ethane carbon of the ligand backbone. In the case of the n-PrO-derivative, the tris(salicylaldimine) ligand was additionally substituted with methoxy groups in the 5-position of the aromatic rings. The 67Ga and 68Ga-complexes of these ligands were prepared by ligand exchange from 67Ga- or 68Ga-acetylacetonate in ethanol. The nonradioactive Ga[(sal)3tame-O-iso-Bu] complex was similarly prepared and shown by x-ray crystallography to exhibit the expected pseudo-octahedral N3O3(3-) coordination sphere about the Ga3+ center. These Ga-radiotracers are highly lipophilic, as demonstrated by their octanol/water partition coefficients. Log P values of 3.1, 3.1, 2.6, and 2.5 were found for the [(sal)3tame-O-iso-Bu], [(sal)3tame-O-n-Bu], [(sal)3tame-O-sec-Bu], and [(5-MeOsal)3tame-O-n-Pr] complexes, respectively. Following intravenous injection into rats, these complexes are rapidly cleared from the blood and exhibit significant myocardial uptake. At 1 min postinjection, 2.4%, 2.0%, 2.1% and 1.1% of the injected dose was found in the heart for the iso-BuO, n-BuO, sec-BuO, and n-PrO complexes, respectively, dropping to 1.0%, 0.8%, 0.8%, and 0.7% at 5 min. The corresponding heart-to-blood ratios are quite high: 17 +/- 3, 14 +/- 2, 12 +/- 2 and 3.5 +/- 0.4 at 1 min and 14 +/- 4, 10 +/- 1, 10 +/- 1 and 3.2 +/- 0.1 at 5 min postinjection. High quality myocardial images were obtained with PET in a normal dog using data collected from 2 to 10 min following intravenous injection of 68Ga[(sal)3tame-O-iso-Bu].

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8429341

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  6 in total

Review 1.  Emerging Tracers for Nuclear Cardiac PET Imaging.

Authors:  Dong-Yeon Kim; Sang-Geon Cho; Hee-Seung Bom
Journal:  Nucl Med Mol Imaging       Date:  2018-05-08

2.  Synthesis and biodistribution of lipophilic and monocationic gallium radiopharmaceuticals derived from N,N'-bis(3-aminopropyl)-N,N'-dimethylethylenediamine: potential agents for PET myocardial imaging with 68Ga.

Authors:  Yui-May Hsiao; Carla J Mathias; Shiaw-Pyng Wey; Phillip E Fanwick; Mark A Green
Journal:  Nucl Med Biol       Date:  2009-01       Impact factor: 2.408

3.  In vitro and in vivo structure-property relationship of (68)Ga-labeled Schiff base derivatives for functional myocardial pet imaging.

Authors:  Oliver Thews; Melanie Zimny; Elisabeth Eppard; Markus Piel; Nicole Bausbacher; Verena Nagel; Frank Rösch
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

4.  Preparation and biodistribution studies of a radiogallium-acetylacetonate bis (thiosemicarbazone) complex in tumor-bearing rodents.

Authors:  Amir Reza Jalilian; Hassan Yousefnia; Kamaleddin Shafaii; Aytak Novinrouz; Amir Abbas Rajamand
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

5.  Evaluation of 68Ga-labeled MG7 antibody: a targeted probe for PET/CT imaging of gastric cancer.

Authors:  Bing Xu; Xiaowei Li; Jipeng Yin; Cong Liang; Lijuan Liu; Zhaoyan Qiu; Liping Yao; Yongzhan Nie; Jing Wang; Kaichun Wu
Journal:  Sci Rep       Date:  2015-03-03       Impact factor: 4.379

6.  Crystal structures of {1,1,1-tris-[(salicylaldimino)-meth-yl]ethane}-gallium as both a pyridine solvate and an aceto-nitrile 0.75-solvate and {1,1,1-tris[(salicylaldimino)-meth-yl]ethane}-indium di-chloro-methane solvate.

Authors:  Dominic L Ventura; William W Brennessel; William S Durfee
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2020-04-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.